A股異動丨新研股份(300159.SZ)逆勢大漲近9% 子公司明日宇航擬引入不超8億元增資
格隆匯7月8日丨新研股份(300159.SZ)逆勢大漲近9%,報3.57元,總市值53億元。

新研股份昨晚公吿,公司控股子公司四川明日宇航工業有限責任公司與德陽發展控股集團有限公司和嘉興華控騰匯股權投資合夥企業(有限合夥)簽訂《股權融資之框架協議》,德陽發展、嘉興騰匯擬分別嚮明日宇航增資不超過4億元,總額不超過8億元。
本次增資在完成有關政府部門合法合規的登記備案或者核准手續後經過公司董事會、股東大會審批後方可實施。明日宇航獲得的本次股權投資資金將用於償付供應商欠款、歸還銀行等機構借款和補充經營性流動資金等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.